High-contrast nulling in photonic meshes through architectural redundancy
Optics Letters · 01.06.2025 · 50 (11) · 3660
DOI: 10.1364/ol.558772 ↗Kurz gefasst
Fachartikel in der Zeitschrift Optics Letters, online erschienen am 27.05.2025. Verfasst von Carson G Valdez und 4 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Air Force Office of Scientific Research, Ames Research Center, Stanford Engineering.
Abstract (Originalsprache)
We demonstrate a silicon photonic architecture comprising double Mach–Zehnder interferometers (DMZIs) designed for high-contrast photonic applications. This configuration significantly enhances the achievable extinction ratio of photonic integrated circuits (PICs), reaching levels exceeding 80 dB. By leveraging the tunable properties of DMZIs and implementing a systematic configuration algorithm, the proposed mesh effectively compensates for fabrication imperfections and mitigates non-idealities such as backreflections. Experimental validation on a silicon-on-insulator platform demonstrates the potential of this approach for applications requiring high-contrast nulling such as astronomical sensing.
Förderung
- Air Force Office of Scientific Research
- Ames Research Center
- Stanford Engineering
Zitieren
APA
Valdez, C. G., Sun, Z., Kroo, A. R., Miller, D. A. B., & Solgaard, O. (2025). High-contrast nulling in photonic meshes through architectural redundancy. Optics Letters, 50(11), 3660. https://doi.org/10.1364/ol.558772
Vancouver
Valdez CG, Sun Z, Kroo AR, Miller DAB, Solgaard O. High-contrast nulling in photonic meshes through architectural redundancy. Optics Letters. 2025;50(11):3660. doi:10.1364/ol.558772
BibTeX
@article{Valdez2025,
author = {Valdez, Carson G and Sun, Zhanghao and Kroo, Anne R and Miller, David A B and Solgaard, Olav},
title = {High-contrast nulling in photonic meshes through architectural redundancy},
journal = {Optics Letters},
year = {2025},
volume = {50},
number = {11},
pages = {3660},
doi = {10.1364/ol.558772}
}
EUVIMED